Konstantinos Chouliaras1, Edward A Levine1, Nora Fino2, Perry Shen1, Konstantinos I Votanopoulos3. 1. Surgical Oncology Service, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC, USA. 2. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. 3. Surgical Oncology Service, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.
Abstract
BACKGROUND: Gastrointestinal leak (GIL) after cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is associated with significant morbidity and mortality. This study aimed to identify GIL prognostic factors and its impact on overall survival. METHODS: A retrospective analysis of a prospectively maintained database comprising 1270 CRS/HIPEC procedures was performed. Type of GIL, functional and resection status, morbidity, mortality, and survival were reviewed. RESULTS: Gastrointestinal leaks were identified in 8.7% (110/1270) of CRS/HIPEC procedures, including 53 anastomotic leaks (4.2%), 53 hollow viscus perforations (4.2%), and four leaks at unknown sites. The multivariate predictors of leak were Eastern Cooperative Oncology Group (ECOG) functional status (ECOG 1 vs. 0: odds ratio [OR] 2.12, p = 0.009; ECOG 2 vs. 0: OR 2.90, p = 0.004), and number of anastomoses (OR 5.34; p < 0.0001). The in-hospital mortality rate for the GIL cohort was 21.8% (24/110), with a 72% (80/110) reoperation rate. The leak cohort had a higher major morbidity rate (88.3 vs. 23.3%; p < 0.0001), a longer hospital stay (39.0 vs. 9.9 days; p < 0.0001), and a longer intensive care unit (ICU) stay (7.7 vs. 1.7 days; p = 0.0003). After surgical mortality was excluded, the overall survival periods for the leak and no-leak patients with complete cytoreduction were respectively 1.5 and 4.98 years (p = 0.0001). Clinically significant decreases in survival were observed for all primary malignancies. CONCLUSIONS: Gastrointestinal leak after CRS/HIPEC is a source of significant mortality, with a decrease in overall survival even after complete CRS. Preoperative functional status and number of anastomoses are predictors of leak for CRS/HIPEC patients.
BACKGROUND:Gastrointestinal leak (GIL) after cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC) is associated with significant morbidity and mortality. This study aimed to identify GIL prognostic factors and its impact on overall survival. METHODS: A retrospective analysis of a prospectively maintained database comprising 1270 CRS/HIPEC procedures was performed. Type of GIL, functional and resection status, morbidity, mortality, and survival were reviewed. RESULTS:Gastrointestinal leaks were identified in 8.7% (110/1270) of CRS/HIPEC procedures, including 53 anastomotic leaks (4.2%), 53 hollow viscus perforations (4.2%), and four leaks at unknown sites. The multivariate predictors of leak were Eastern Cooperative Oncology Group (ECOG) functional status (ECOG 1 vs. 0: odds ratio [OR] 2.12, p = 0.009; ECOG 2 vs. 0: OR 2.90, p = 0.004), and number of anastomoses (OR 5.34; p < 0.0001). The in-hospital mortality rate for the GIL cohort was 21.8% (24/110), with a 72% (80/110) reoperation rate. The leak cohort had a higher major morbidity rate (88.3 vs. 23.3%; p < 0.0001), a longer hospital stay (39.0 vs. 9.9 days; p < 0.0001), and a longer intensive care unit (ICU) stay (7.7 vs. 1.7 days; p = 0.0003). After surgical mortality was excluded, the overall survival periods for the leak and no-leak patients with complete cytoreduction were respectively 1.5 and 4.98 years (p = 0.0001). Clinically significant decreases in survival were observed for all primary malignancies. CONCLUSIONS:Gastrointestinal leak after CRS/HIPEC is a source of significant mortality, with a decrease in overall survival even after complete CRS. Preoperative functional status and number of anastomoses are predictors of leak for CRS/HIPECpatients.
Authors: Edmund K Bartlett; Chelsey Meise; Robert E Roses; Douglas L Fraker; Rachel R Kelz; Giorgos C Karakousis Journal: Ann Surg Oncol Date: 2013-08-29 Impact factor: 5.344
Authors: Chukwuemeka U Ihemelandu; Richard McQuellon; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine Journal: Ann Surg Oncol Date: 2013-06-08 Impact factor: 5.344
Authors: Michael Thornton; Heman Joshi; Chandrakumar Vimalachandran; Richard Heath; Paul Carter; Ufuk Gur; Paul Rooney Journal: Int J Colorectal Dis Date: 2010-11-25 Impact factor: 2.571
Authors: Edward A Levine; John H Stewart; Gregory B Russell; Kim R Geisinger; Brian L Loggie; Perry Shen Journal: J Am Coll Surg Date: 2007-05 Impact factor: 6.113
Authors: Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos Journal: J Am Coll Surg Date: 2013-12-21 Impact factor: 6.113
Authors: S P Somashekhar; Kumar C Rohit; Yethadka Ramya; Shabber S Zaveri; Vijay Ahuja; Arun Kumar Namachivayam; K R Ashwin Journal: Ann Surg Oncol Date: 2021-08-30 Impact factor: 5.344
Authors: Karol Rawicz-Pruszyński; Katarzyna Sędłak; Radosław Mlak; Jerzy Mielko; Wojciech P Polkowski Journal: Cancers (Basel) Date: 2020-06-26 Impact factor: 6.639
Authors: Lisa Überrück; Giorgi Nadiradze; Can Yurttas; Alfred Königsrainer; Ingmar Königsrainer; Philipp Horvath Journal: Ann Surg Oncol Date: 2020-11-09 Impact factor: 5.344